SCHEMBL8647181

SCHEMBL8647181

CC(=O)N[C@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O[C@@H]1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ POLB P06746 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ CA1 P00915 6/20 0.50
▸ CA2 P00918 6/20 0.50
▸ CA9 Q16790 6/20 0.50
▸ CA12 O43570 5/20 0.50
▸ CYP3A4 P08684 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ THRB P10828 2/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ TSHR P16473 1/20 0.48
▸ NR3C1 P04150 1/20 0.48
▸ FYN P06241 1/20 0.48
▸ ADRA2A P08913 1/20 0.48
▸ ADORA3 P0DMS8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8647178 1.00 LMNA (0.57) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL19477874 1.00 LMNA (0.57) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL5148124 1.00 LMNA (0.57) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL2338780 1.00 LMNA (0.57) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL20643514 1.00 LMNA (0.57) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL10036857 1.00 LMNA (0.57) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL19477779 1.00 LMNA (0.57) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL22537923 1.00 LMNA (0.57) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL21762059 1.00 LMNA (0.57) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL3986108 1.00 LMNA (0.57) LMNAKMT2APOLBALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052134-B1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME (US) 2021-05-05 — — EP disclosed
US-20180110863-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2018-04-26 — — US disclosed
EP-3280450-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES Merck Sharp & Dohme Corp. (US) 2018-02-14 — — EP disclosed
US-9889205-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME CORP. (US) 2018-02-13 — — US disclosed
US-20160303244-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2016-10-20 — — US disclosed
WO-2016164288-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2016-10-13 — — WO disclosed
US-9427475-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME CORP. (US) 2016-08-30 — — US disclosed
US-20150105317-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME LLC 2015-04-16 — — US disclosed
US-5756712-A REPLACING THE ETHER OXYGEN LINKAGE OF OLIGOSACCHARIDES WITH A PEPTIDE LINK, WHERE THE NITROGEN ATOM IS LINKED TO THE ANOMERIC CARBON ATOM OF THE SUGAR E. I. DU PONT DE NEMOURS AND COMPANY (US) 1998-05-26 — — US disclosed
EP-0553297-B1 PROCESS FOR THE PREPARATION OF GLYCOSYL PHOSPHATE TRIESTERS DU PONT (US) 1995-01-25 — — EP disclosed
US-5288859-A Reacting metal azide with glycosyl phosphate triester E. I. DU PONT DE NEMOURS AND COMPANY (US) 1994-02-22 — — US disclosed
EP-0553297-A1 PROCESS FOR THE PREPARATION OF GLYCOSYL PHOSPHATE TRIESTERS. DU PONT (US) 1993-08-04 — — EP disclosed
WO-1992009612-A1 PROCESS FOR THE PREPARATION OF GLYCOSYL PHOSPHATE TRIESTERS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1992-06-11 — — WO disclosed
US-5095123-A Phosphorylation E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-03-10 — — US disclosed
US-4792615-A HYDROLYSIS OF A-DIHYDROPOLYPRENYL DICHLOROPHOSPHATE WITH ALKALI OR ALKALINE EARTH METAL HYDROXIDE; POLYISOPRENE NAKAGAWA NAOSHI (JP) 1988-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180110863-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 LMNA 3810/4885KMT2A 2547/4885POLB 4628/4885
US-20150105317-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 LMNA 3539/4885KMT2A 2821/4885POLB 4705/4885
US-20160303244-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 LMNA 3539/4885KMT2A 2821/4885POLB 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback